Ageing - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 53
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AFDC2AA478BEN
Leaflet:

Download PDF Leaflet

Ageing - Pipeline Review, H2 2016
Ageing - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ageing - Pipeline Review, H2 2016, provides an overview of the Ageing (Metabolic Disorders) pipeline landscape.

Ageing is the accumulation of changes in a person over time. Symptoms include stooped posture, constipation, and increased susceptibility to infection, risk of heat stroke or hypothermia, decrease in visual acuity, wrinkling and sagging skin, and diminished peripheral vision.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ageing - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ageing (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ageing (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ageing and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively for Ageing.

Ageing (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ageing (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Ageing (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ageing (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ageing (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ageing (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ageing (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ageing (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Ageing Overview
Therapeutics Development
Pipeline Products for Ageing - Overview
Pipeline Products for Ageing - Comparative Analysis
Ageing - Therapeutics under Development by Companies
Ageing - Therapeutics under Investigation by Universities/Institutes
Ageing - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Ageing - Products under Development by Companies
Ageing - Products under Investigation by Universities/Institutes
Ageing - Companies Involved in Therapeutics Development
Generon (Shanghai) Corporation Ltd.
Mapreg S.A.S.
RepliCel Life Sciences, Inc.
RXi Pharmaceuticals Corporation
Saje Pharma, LLC
Theravasc, Inc.
Ageing - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AGS-499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BQ-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Ageing - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-899 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAP-46 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMP-26051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMP-26052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium nitrite SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPL-891.1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ageing - Dormant Projects
Ageing - Product Development Milestones
Featured News & Press Releases
Apr 20, 2016: RepliCel Life Sciences Finishes Enrolment for its Skin Rejuvenation Clinical Trial
Dec 17, 2015: RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin
Sep 15, 2015: RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study
Jul 21, 2015: RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial
Feb 23, 2015: RepliCel Submits Clinical Trial Application for its Dermatological Clinical Trial
Oct 09, 2014: RepliCel to Present Commercial and Clinical Update on RCS-01 at BioJapan 2014 World Business Forum
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 53

LIST OF TABLES

Number of Products under Development for Ageing, H2 2016
Number of Products under Development for Ageing - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Ageing - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016
Ageing - Pipeline by Mapreg S.A.S., H2 2016
Ageing - Pipeline by RepliCel Life Sciences, Inc., H2 2016
Ageing - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
Ageing - Pipeline by Saje Pharma, LLC, H2 2016
Ageing - Pipeline by Theravasc, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Ageing - Dormant Projects, H2 2016 46

LIST OF FIGURES

Number of Products under Development for Ageing, H2 2016
Number of Products under Development for Ageing - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


ThromboGenics NV - Product Pipeline Review - 2015 US$ 1,200.00 Jun, 2015 · 33 pages

Ask Your Question

Ageing - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: